Relapse postautograft in acute myeloid leukaemia (AML), may in part arise from leukaemia cells present in the bone marrow (BM) inoculum, and the level of minimal residual disease (MRD) in BM harvests used for autografting may therefore be clinically important.We have used the WT1 transcript as a marker of MRD, which was quantitated by RQ-PCR, in the BM harvests of 24 patients receiving an ABMT for AML. ABL was used as a control gene with WT1 level being normalised to 10 5 copies of ABL per sample. Median WT1 level was 651 copies (range ¼ 113-32 700) for the 13 patients with relapse-free survival (RFS) of less than 5 years, and 174 (range ¼ 0-1900) for patients with RFS of over 5 years postautograft (Po0.04). The RFS was 10.5 months for patients with WT1 level of 42000 copies (n ¼ 5), and has not yet been reached for patients with WT1 levelo2000 (n ¼ 21), at a median follow-up of 92 months (Po0.05). We show that elevated levels of MRD in BM harvests are associated with a higher relapse risk in patients autografted for AML.
marrow harvests; autograft; MRD Autologous bone marrow transplantation (ABMT), as consolidation therapy, can prolong disease-free survival (RFS) for patients with acute myeloid leukaemia (AML) in first CR.
1-3 However, relapse remains the main cause of treatment failure, and may in part arise from leukaemia cells present in the bone marrow (BM) inoculum. 4 Thus, the level of minimal residual disease (MRD) in BM harvests may be relevant in determining the risk of relapse. Methods of detection of MRD with increased sensitivity, such as RQ-PCR are now available and quantitation of WT1 is useful in patients who lack specific fusion transcripts. This gene is overexpressed in over 90% of leukaemia cells and several studies have shown that quantitation of WT1 transcripts for patients in remission has prognostic value. [5] [6] [7] [8] This study was undertaken to measure MRD levels in BM harvests used for autografting in AML, through WT1 quantitation, and to correlate these results with clinical outcome.
Materials and methods

Patients
BM harvest samples were available from 24 patients who had received an ABMT as consolidation treatment for AML between 1987 and 2000 (Table 1 ). There were 14 female and 10 male patients, with a median age of 42.5 years (range . Cytogenetics analysis at diagnosis showed two patients to be in a poor prognostic and 17 in a standard prognostic group using UK MRC criteria. 9 Five patients were in a favourable prognostic group (two with t(15;17), two with inv16, and one with t(8:21)) because the autograft was performed before risk stratification by cytogenetic analysis came into practice. Induction and consolidation treatments were given as per UK MRC 10 and 12 trials and responding patients were autografted after two courses of consolidation treatment. All patients were in morphological and cytogenetic remission at the time of BM harvest and also at autografting. A total of 18 patients were in 1st CR, five in 2nd and one in 3rd CR. 
Sample preparation and quantitation of WT1 transcripts
Mononuclear cells were isolated using Ficoll-Hypaque density gradient centrifugation and stored at À801C. Extraction of RNA and cDNA synthesis was as previously described. 8, 10 Quantitation of WT1 transcript was performed using real-time-PCR. The housekeeping gene ABL was used as the control gene for these quantifications. Equal degradation rates for ABL and WT1 transcripts have previously been described. Amplification reactions were carried out using the ABI Prism 7700 Sequence Detector System. In all, 2 ml cDNA was added to each reaction (25 ml) and a 40-cycle amplification was then performed. All reactions were run in duplicate. Standard curves were prepared from constructs for both WT1 and ABL and used to quantify the copy numbers of both transcripts present in each sample. The reproducibility of both assays was tested by serial dilutions of the constructs on five separate occasions. The average standard curve for the WT1 construct was: slope À3.389 (70.18), Y-intercept 38.07 (71.2), r 2 0.997: and for the ABL construct: slope -3.304 (70.12), Y-intercept 37.14 (70.8), r 2 0.997. The constructs were prepared by PCR amplification of both transcripts from NB4 cell line. Each PCR produced construct was purified using Microcon columns and quantified. WT1 copy number was expressed relative to 10 5 copies of ABL per sample to allow for variability in cDNA quantity in each sample. All negative WT1 results in BM harvests tested were excluded if the sample yielded less than 1000 copies of ABL per sample. Statistical analysis was made using GraphPad Prism version 4.01 for Windows, GraphPad Software, San Diego CA, USA, tests for significant differences in median RFS were made using the Mann-Whitney test, differences in survival curves were analysed using the log-rank test.
Results
A total of 13 patients had relapsed by 5 years postautograft. For those patients with an RFS of less than 5 years, median WT1 copy number in the BM inoculum was 651 copies (range ¼ 113-32 700, mean ¼ 4081). For patients with an RFS of greater than 5 years, median WT1 copy number was 174 copies (range ¼ 0-1900, mean ¼ 500) (I Po0.04). The median RFS was 10.5 months for patients with WT1 level of 42000 copies (n ¼ 5), and has not yet been reached for patients with WT1 levelo2000 (n ¼ 21), at a median follow-up of 94 months (Po0.02). No significant difference in median RFS was noted for increasing age in this series. With regards to cytogenetics, the median RFS for standard risk patients was 21 months, and for good risk patients has not been reached at a median follow-up of 142 months (Figures 1 and 2) . WT1 levels were measured in 10 normal donor BMs and the median copy number was 247 copies (range 10-740), which was lower than the median WT1 level in patients with RFSo5 years (Po0.04), but not significantly different to WT1 levels in patients with a longer RFS.
Discussion
We show that real-time quantitation of WT1 transcripts, as a marker of MRD, is a sensitive technique that can be applied to BM harvests, and also has prognostic signifi- cance. High levels of contaminating residual leukaemia cells present in the BM harvest used for autografting, are associated with a high risk of relapse. This correlates well with other studies of MRD. For patients that were randomised to receive an autograft as part of the UK MRC AML 10 trial, persistence of the diagnostic cytogenetic abnormality at the time of BM harvest was also associated with a poor prognosis. 11 However, MRD was detected in less than 10% of patients using this method. Studies in AML using flow cytometry have demonstrated that the levels of cells expressing an aberrant phenotype in BM harvests correlated with disease recurrence.
12 MRD detection using RQ-PCR is preferable due to its increased sensitivity. The RQ-PCR measurement of WT1 levels is especially useful as a high percentage of patients have high levels at diagnosis and relapse, including those patients who have no specific marker for detection of MRD. 8 Our results are also in accordance with those for MRD quantitation in BM harvests used for autografting in ALL, where higher MRD levels detected by PCR were associated with a worse RFS. 13 It could be argued that higher WT1 levels may merely reflect higher CD34 counts in BM harvests. CD34 counting was not performed routinely on BM harvests during the early part of this study. However, no correlation was found between WT1 level and nucleated cell count in each harvest. High levels of MRD present in the BM harvests may be reflecting high levels of MRD in the patient at the time of harvest and hence lead to a higher relapse rate. It is, however, known that MRD present in the BM inoculum is in part responsible for relapse, 4 and a reduction in relapse rate has been observed if the BM harvest is purged ex vivo, 14, 15 although the role of purging in ABMT for AML has remained controversial. The higher levels of MRD in BM harvests, as measured by RQ-PCR, may therefore be contributing to the increased rate of relapse. It would also be useful to measure WT1 levels in PBSC harvests in the setting of autografting since PBSC collections from patients with AML have higher WT1 levels than from patients with solid malignancies. WT1 levels have been noted to be higher in patients with a RFS of less than 12 months than for patients with a longer RFS, 16 although this difference was not statistically significant and only seven patients with AML were included in this study. Although the number of patients is relatively small, our study represents the largest of its kind, using WT1 as a marker of MRD. We conclude that RQ-PCR of WT1 transcripts can be used for MRD quantitation in BM harvests and show that higher MRD levels are associated with an increased risk of relapse in patients autografted for AML. We also suggest that patients with high MRD levels (42000 WT1 copies) should not be autografted but instead be considered for allogeneic stem cell transplantation because of their poor outcome. WT1 quantification of bone marrow harvests in AML D Osborne et al
